Home > Newsletters > Drug Industry Daily > Novartis Eyes Job Cuts, Plans for $1.22 Billion Hit on Pipeline, Patent Setbacks
Drug Industry Daily
Jan. 16, 2012 | Vol. 11 No. 10
Novartis Eyes Job Cuts, Plans for $1.22 Billion Hit on Pipeline, Patent Setbacks
Novartis is looking to job cuts and charges of $1.22 billion to help it weather withering revenues from the coming patent loss of blockbuster hypertension drug Diovan and possible slashed sales of Tekturna, which performed poorly in a recent clinical trial.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.